Half-Matched stem cell transplant offers hope for children with blood disorders
NCT ID NCT04356469
First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This study tests a new type of stem cell transplant for children with severe blood disorders like sickle cell disease or aplastic anemia. The transplant uses stem cells from a parent or other half-matched family donor, which are specially processed to remove certain immune cells. The goal is to see if this approach is safe and helps the child's body accept the donor cells without serious complications.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- TCR alpha beta T-cell and CD19 B-cell depleted stem cell graft
- What this could lead to
- If successful, this approach could offer a safer transplant option for children with severe blood disorders who lack a fully matched donor.
- What could go wrong
- This is a small Phase 2 study, so results may not apply broadly. Risks include graft failure, infection, or graft-versus-host disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 17 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2020
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
0 to 21 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Severe sickle cell disease (HbSS, HbSC, HbSB0, HbSB+, HbSD, HbSE) with at least one of the following criteria: 1. Cerebrovascular accident lasting longer than 24 hours 2. Impaired neuropsychological function with abnormal brain MRI/MRA 3. Patients with frequent (≥ 3 per year for preceding 2 years) painful vaso-occlusive episodes 4. Recurrent (≥ 3 in lifetime) acute chest syndrome events which have necessitated erythrocyte transfusion therapy 5. Any combination of ≥ 3 acute chest syndrome episodes and vaso-occlusive pain episodes yearly for 3 years and have failed treatment with hydroxyurea (HU) (at least 6 months on maximum tolerated dose) or who are intolerant to HU therapy 2. Thalassemia major with at least one of the following criteria: 1. Transfusion dependency defined as receiving 8 or more transfusions per year 2. Thalassemia diagnosis documented by clinical assessment, laboratory evidence with microcytic anemia and absence of HbA (\< 10%) on electrophoresis and or confirmation by DNA analysis of alpha and beta gene loci 3. Genotypically proven thalassemia major for children \< 2 years of age even in the absence of transfusion dependency 4. Lucarelli class 1 or 2 risk status (i.e. with only 0-2 of the following factors: hepatomegaly, portal fibrosis, or poor response to chelation therapy) 3. Bone marrow failure syndromes and autoimmune cytopenias: 1. Severe Aplastic Anemia refractory to immunosuppressive therapy 2. Diamond Blackfan Anemia refractory to conventional therapy 3. Inherited Bone Marrow Failure Syndromes such as Fanconi anemia and Shwachman-Diamond syndrome with progressive marrow failure (without cytogenetic evidence of MDS/AML) 4. Severe Congenital Neutropenia 5. Congenital Amegakaryocytic Thrombocytopenia 6. Glanzmann Thrombasthenia 7. Autoimmune Cytopenias refractory to conventional treatment (including Pure red cell aplasia, Evan's syndrome, Immune thrombocytopenia, autoimmune hemolytic anemia) 8. Other marrow failure disorders not otherwise specified Inclusion Criteria: 1. Patient has a suitable genotypic identical match of 5/10. The donor and recipient must be identical, as determined by high resolution typing, at least one allele of each of the following genetic loci: HLA-A, HLA-B, HLA-C, HLA-DRB1 and HLA-DQB1. 2. Patients must have adequate organ function measured by: 1. Cardiac: asymptomatic or if symptomatic then LVEF at rest must be ≥ 40% or SF ≥ 26% 2. Pulmonary: asymptomatic or if symptomatic DLCO ≥ 40% of predicted (corrected for hemoglobin) or pulse oximetry ≥ 92% on room air if the patient is unable to perform pulmonary function testing. 3. Renal: Creatinine clearance (CrCl) or glomerular filtration rate (GFR) must be \> 50 mL/min/1.73 m2. 4. Hepatic: Serum conjugated (direct) bilirubin \< 2.0 x ULN for age as per local laboratory unless attributable to Gilbert's syndrome; AST and ALT \< 5.0 x ULN for age as per local laboratory. Patients with hyperbilirubinemia as a consequence of hyperhemolysis, or a profound change in serum hemoglobin post blood transfusion, are not excluded. 5. Karnofsky or Lansky (age-dependent) performance score ≥ 50 3. Signed written informed consent Exclusion Criteria: 1. Participants who have an HLA-matched sibling who is able and willing to donate bone marrow. Patients with a HLA-matched unrelated donors are not excluded. 2. Pregnant or breastfeeding females. 3. Patient has HIV or uncontrolled fungal, bacterial or viral infections. 4. Patient has received prior solid organ transplant. 5. Patient has active GVHD (\> grade II) or chronic extensive GVHD due to a previous allograft at the time of inclusion. 6. For patients with hemoglobinopathy, liver biopsy is necessary if the patient has received chronic transfusions for over a year and has two ferritin levels of ≥ 1000 ng/ml. Patients with cirrhosis, extensive bridging hepatic fibrosis, or active hepatitis are excluded from enrollment.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bone marrow failure syndrome are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Johns Hopkins All Children's Hospital
RECRUITINGSt. Petersburg, Florida, 33701, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Half-Matched stem cells tested as a cure for severe aplastic anemia
- Half-Matched stem cell transplants tested as a cure path for older aplastic anemia patients
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
- New stem cell processing method offers hope for patients without a perfect donor match
- New transplant approach aims to tame bone marrow failure
- New trial aims to slash deadly bloodstream infections from hospital tubes